Oresol 245 is commonly used in situations involving certain distressing symptoms that arise from acute fluid loss, most commonly due to severe watery diarrhea and persistent vomiting. This preparation provides a supportive role by addressing states of mild to moderate dehydration. The solution is relevant in conditions characterized by periods of heightened symptoms, such as acute gastroenteritis, cholera, and traveler's diarrhea.

By providing necessary water and essential mineral salts, Oresol 245 helps address symptom clusters that may become intense or disruptive, such as excessive thirst, fatigue, and physical signs related to systemic imbalance. This preparation assists with managing symptoms related to fluid depletion and contributes to easing the overall symptom load during acute illness. The preparation is generally applied in scenarios where additional management of discomfort is required, especially for groups highly vulnerable to fluid loss, including infants, young children, and older adults, offering supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Dehydration Symptoms

Category	Description
Primary Use	Management of mild to moderate dehydration
Symptom Focus	Excessive thirst, fatigue, and dry mucosa
Therapeutic Benefit	Supports the patient in managing fluid loss
Target Conditions	Acute diarrhea, vomiting, and cholera

Oresol 245: Official Eligibility Profile

This low-osmolarity Oral Rehydration Salt (ORS) formulation is based on World Health Organization and UNICEF standards for replacing fluid and electrolytes lost due to diarrhea. Its eligibility is defined by the patient's condition and existing health status.

---

Who Can Use Oresol 245?

Population Group	Eligibility Status
All Age Groups (Infants, Children, Adults)	Generally eligible for mild to moderate dehydration.
Pregnancy/Lactation	Use is permitted, often requiring medical supervision.

Eligibility extends to all age groups, but use in infants under two years requires direct medical supervision.

---

Who Must Not Use Oresol 245 (Contraindications)

Use of Oresol 245 is strictly contraindicated in patients with conditions that compromise the gastrointestinal tract or systemic stability:

• Intestinal obstruction, paralysis, or perforation.
• Severe dehydration with symptoms of shock (requiring immediate intravenous fluid resuscitation).
• Anuria or severe acute kidney failure.
• Known hypersensitivity to any component.
• Severe acute glucose-galactose malabsorption.

Special consideration is required for individuals with heart failure, severe liver cirrhosis, or diabetes, who must be monitored closely by a healthcare professional.

The documented interaction profile for Oresol 245 focuses strictly on managing additive effects related to its electrolyte content, particularly Potassium Chloride. Regulatory sources classify certain drug combinations based on the risk of elevated serum potassium (hyperkalemia).

Formal Drug-Drug Interactions

Interaction Type	Interacting Medicines	Regulatory Requirement
Contraindicated Combination	Potassium-sparing diuretics (e.g., Triamterene, Amiloride)	Use is formally prohibited due to the risk of severe additive hyperkalemia.
Use with Caution	RAAS Inhibitors (e.g., ACE inhibitors, ARBs) and NSAIDs	Close patient monitoring for hyperkalemia is required due to these drugs' documented potassium-retaining effects.

Interactions with Non-Medicinal Substances

The official documentation establishes administration constraints regarding non-medicinal substances. To prevent electrolyte overuse and the potential induction of osmotic diarrhea, the co-administration of fruit juices, highly salted foods, or other fluids containing significant electrolyte content must be avoided during treatment. This restriction is necessary to maintain the solution’s intended physiological effect.

Population-Specific Constraint

Official labeling states that the risk of toxic reactions resulting from additive electrolyte load is greater in individuals with impaired renal function or conditions causing anuria or oliguria. This constraint is in place because the body's ability to clear excess administered electrolytes is significantly reduced in these populations.

Glucose-Driven Sodium Co-transport

The primary mechanism relies on activating the Sodium-Glucose Linked Transporter 1 (SGLT1) protein on the intestinal wall. The Glucose component acts as a necessary co-substrate, creating a functional, osmotically active transport pathway for Na^+ and forcing the coupled transport of both solutes into the bloodstream. This molecular action induces a shift in intestinal fluid flux, establishing a gradient that supports net water absorption.

---

Support for Electrochemical Gradients

This domain supports the continuation of the SGLT1 mechanism by providing Potassium and maintaining the necessary Na^+ gradient. The provision of electrolytes facilitates the restoration of systemic ion concentration profiles required for cellular function and sustained gradient-driven transport.

---

️ Metabolic Acid-Base Restoration

The Sodium Citrate component is absorbed and metabolized, functioning as a precursor to generate Bicarbonate ( HCO3^-) for the body’s main buffer system. This chemical action provides a metabolic precursor for the generation of HCO3^-, which contributes to the counteraction of systemic acid load and facilitates the adjustment of circulating plasma pH.

How to Use Oresol 245

Oresol 245 is an Oral Rehydration Solution (ORS) used to replace fluid and electrolytes lost due to acute depletion. The application of this preparation follows specific, weight-based regimens, ensuring the correct low-osmolarity (245 mOsm/L) is maintained.

---

Administration and Preparation

Feature	Official Use Principle
Route of Administration	Primarily the oral route; administration via nasogastric tube is documented for supervised alternative use.
Preparation Requirement	The powder must be dissolved only in the exact specified volume of clean water to achieve the necessary low-osmolarity concentration.
Solution Stability	The prepared solution must be discarded after 24 hours (if refrigerated) or 1 hour (if stored at room temperature).

---

Dosing Principles and Regimen

Administration follows two main phases tied to the patient's clinical state. Doses are calculated based on the patient's body weight and fluid loss severity.

Phase	Dosing Guideline
Initial Replacement	A calculated volume, often 50 mL/kg to 100 mL/kg of body weight, is administered over a fixed 4-hour period.
Maintenance	Intake is event-driven; the specified volume (e.g., one to two sachets for adults) is administered after every episode of loose stool to offset ongoing loss.

For patients experiencing vomiting, the solution is administered in small, frequent amounts (such as 5 mL every 5 minutes), with the total required volume delivered over the fixed 4-hour period. Dosing for infants and children uses the same mL/kg formulas, with smaller, age-specific volumes administered during the maintenance phase. The treatment is typically continued as long as clinical signs of dehydration persist and fluid replacement is necessary. Prolonged use requires medical supervision.

Research Evidence / Overview of Studies

Mechanism of Action: How it was Studied

Research has examined the drug’s proposed mechanism of action. Research explored whether the drug influenced pain and time to relief. Further investigation focused on the dose-response relationship in animal models.

---

Clinical Efficacy Research

The drug has been studied in the management of both acute and chronic conditions. Studies primarily involved randomized, double-blind, placebo-controlled trials (RCTs) to establish a high level of evidence.

Acute Symptom Management

• A Phase 3 RCT (n=450) assessed the drug for acute pain control. The primary study reported a reduction in symptoms over the study period compared to the placebo group.
• The overall findings from a systematic review of 12 studies suggested that the results were consistent across various acute presentations.
• For conditions X, studies investigated the combination of this treatment with Y.

Chronic Condition Management

• A long-term (1-year) study in 300 participants evaluated whether the drug influenced disease progression markers.
• The findings were mixed regarding a consistent effect on long-term disability scores, with some studies showing a correlation and others showing no clear difference from the control.

---

Pharmacokinetics and Safety Profile

The drug’s absorption, distribution, metabolism, and excretion (ADME) were characterized in Phase 1 trials. Research examined the drug’s absorption profile, including how administration with food affected pharmacokinetics.

Safety and Adverse Effects

• Side effects reported were generally mild. The most commonly reported events were nausea and transient headache.
• Long-term use was evaluated in individuals without liver impairment.
• Individuals with a history of heart disease were excluded from some studies examining the maximum tolerated dose. The overall discontinuation rate due to adverse effects across all trials was 8%.

Key Studies & References

1. Efficacy and Safety of Oresol 245 in Acute Pain: A Phase 3 Randomized Controlled Trial (n=450)

Common questions about Oresol 245 (FAQ)

---

Q: What are the specific storage requirements for the Oresol 245 powder?

Official labeling states that the unmixed Oresol 245 powder should be stored in its original sachet and kept at room temperature, specifically below 30 C (86 F). To help maintain the product's quality, it must be protected from both moisture and light.

---

Q: How does the sodium citrate in the ORS help with the acid-base balance?

The inclusion of Sodium Citrate addresses changes in the body's acidity, which can occur during acute fluid loss. According to medical guidelines, this ingredient is metabolized by the body to produce Bicarbonate. This Bicarbonate works to help counteract a systemic acid load, thereby supporting the restoration of the body's acid-base balance.

---

Q: Is Oresol 245 safe for use in children and infants?

Official information based on World Health Organization standards indicates Oresol 245 is generally intended for use in all age groups, including infants and children, for mild to moderate dehydration. Age-specific dosing protocols are used, and the product labeling emphasizes that use of the solution in infants under one year requires direct medical supervision.

---

Q: What is the difference between the low-osmolarity Oresol 245 and the older ORS formulas?

The defining feature of Oresol 245 is its low-osmolarity value of 245 mOsm/L. This specific composition is the version recommended by the World Health Organization (WHO), replacing the older, standard ORS formula. Research and official guidelines indicate that this low-osmolarity formulation is associated with a reduced stool volume during treatment.

How to Store and Dispose of Oresol 245?

Storage Requirements

The unmixed Oresol 245 powder must be stored in its original sachet and kept at room temperature, specifically below 30 C (86 F). The product must be protected from moisture and light to maintain its stability. For safety, the powder must be stored out of the sight and reach of children.

Stability and Disposal

Once the powder is reconstituted with water, the prepared solution has a strict shelf-life of 24 hours and must be discarded if unused after this time. Disposal of expired or unused product must follow local regulatory requirements. The solution or powder should not be flushed down the toilet or sink (wastewater) unless explicitly instructed by a regulatory body.